Literature DB >> 28286440

Medical Care of the Patient With Compensated Cirrhosis.

Jorge L Herrera1, Reynaldo Rodríguez1.   

Abstract

The prevalence of liver disease and its complications is rapidly increasing in the United States. Gastroenterologists and hepatologists provide most of the medical care for patients with chronic liver disease and cirrhosis. While most gastroenterologists and hepatologists are comfortable managing the serious complications related to cirrhosis, many fail to provide the necessary education, prevention, and treatment for non-life-threatening problems associated with cirrhosis. Health-related quality of life has been found to strongly correlate with how well cirrhosis-related problems are addressed in the outpatient setting. This paper will review the outpatient management of patients with stable cirrhosis, including the surveillance and health maintenance recommendations necessary to monitor, prevent, or delay the onset of serious complications.

Entities:  

Keywords:  Cirrhosis; hepatocellular carcinoma surveillance; patient education; variceal bleeding prophylaxis

Year:  2006        PMID: 28286440      PMCID: PMC5335628     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  90 in total

Review 1.  Hepatocellular carcinoma: present status and future prospects.

Authors:  Josep M Llovet; Michel Beaugrand
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial.

Authors: 
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

3.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Authors:  Jorge A Marrero; Hero K Hussain; Hahn V Nghiem; Ramsey Umar; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

Review 4.  Evaluation and management of osteoporosis in liver disease.

Authors:  J Eileen Hay; Maureen M J Guichelaar
Journal:  Clin Liver Dis       Date:  2005-11       Impact factor: 6.126

5.  Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.

Authors:  Joan Clària; Jeffrey D Kent; Marta López-Parra; Ginés Escolar; Luís Ruiz-Del-Arbol; Pere Ginès; Wladimiro Jiménez; Boris Vucelic; Vicente Arroyo
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

6.  Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions.

Authors:  A T Banks; H J Zimmerman; K G Ishak; J G Harter
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

Review 7.  Nonalcoholic fatty liver disease.

Authors:  Andy S Yu; Emmet B Keeffe
Journal:  Rev Gastroenterol Disord       Date:  2002

8.  Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival.

Authors:  L Barbara; G Benzi; S Gaiani; F Fusconi; G Zironi; S Siringo; A Rigamonti; C Barbara; W Grigioni; A Mazziotti
Journal:  Hepatology       Date:  1992-07       Impact factor: 17.425

9.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Authors:  Naga Chalasani; Hisham Aljadhey; Joe Kesterson; Michael D Murray; Stephen D Hall
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

10.  Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis.

Authors:  F Wong; D Massie; P Hsu; F Dudley
Journal:  Gastroenterology       Date:  1993-03       Impact factor: 22.682

View more
  1 in total

Review 1.  Structural changes of proteins in liver cirrhosis and consequential changes in their function.

Authors:  Nikola Gligorijević; Simeon Minić; Olgica Nedić
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.